Abstract
Criteria are described for assessing the pharmacological selectivity of new antidepressant drugs in man. The criteria are applied to 10 different types of development of new antidepressant drugs. Only in the case of the 5-HT uptake inhibitors are the criteria satisfied. New antidepressant drugs may be shown to be therapeutically effective but until the criteria of this review are met it will not be possible to decide either how they act or whether other drugs with a similar pharmacological action should be investigated.